Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 70
- Registration Number
- NCT04124302
Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2019-10-09
- Target Recruit Count
- 100
- Registration Number
- NCT04120623
Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 72
- Registration Number
- NCT04019821
- Locations
- 🇵🇱
Department of Pediatric Diabetology and Pediatrics, Pediatric Teaching Clinical Hospital, Warsaw, Poland
Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 525
- Registration Number
- NCT04012138
- Locations
- 🇫🇷
Agen Hospital, Agen, France
🇫🇷Angers University Hospital, Angers, France
🇫🇷University Hospital, Clermont-Ferrand, Clermont-Ferrand, France
Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Newly Diagnosed Type 2 Diabetes
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 260
- Registration Number
- NCT03987308
- Locations
- 🇨🇳
First Hospital of Peking University, Beijing, China,Beijing, China
🇨🇳Ninth Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Fuzhou, China,Fuzhou, China
🇨🇳Heilongjiang provincial hospital, Harbin, China,Harbin, China
Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 52
- Registration Number
- NCT03916601
- Locations
- 🇩🇪
Investigational Site Number 2760001, Neuss, Germany
Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
- Conditions
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 210
- Registration Number
- NCT03874715
- Locations
- 🇺🇸
Investigational Site Number 8400014, Concord, California, United States
🇺🇸Investigational Site Number 8400038, Doral, Florida, United States
🇺🇸Investigational Site Number 8400027, Houston, Texas, United States
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 92
- Registration Number
- NCT03824002
- Locations
- 🇮🇹
Internal Medicine Ward, University of Palermo, Palermo, Italy
IDegLira HIGH Trial
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Emory University
- Target Recruit Count
- 145
- Registration Number
- NCT03737240
- Locations
- 🇺🇸
Emory Clinic, Atlanta, Georgia, United States
🇺🇸Grady Health System, Atlanta, Georgia, United States
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2274
- Registration Number
- NCT03689374
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.